Stock ELDN ELEDON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Eledon Pharmaceuticals, Inc.

Equities

ELDN

US28617K1016

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-08 pm EDT 		5-day change 1st Jan Change
2.44 USD +7.96% Intraday chart for Eledon Pharmaceuticals, Inc. +6.55% +35.56%
May. 07 Eledon Pharmaceuticals, Inc. Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection CI
May. 06 Eledon Pharmaceuticals, Inc. announced that it expects to receive $49.99901 million in funding CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
GL
Eledon Pharmaceuticals, Inc. Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
CI
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
GL
Eledon Pharmaceuticals, Inc. announced that it expects to receive $49.99901 million in funding
CI
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
GL
Eledon Pharmaceuticals Says 12th Participant Enrolled in Tegoprubart Trial; Shares Rise After Hours
MT
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
GL
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
CI
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
MT
Sector Update: Health Care
MT
Eledon Pharmaceuticals Says Tegoprubart Used in Kidney Transplant From Pig to Human
MT
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
GL
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
AQ
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
GL
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ELDN Stock
  4. News Eledon Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW